Lung Cancer

EA5163 / S1709 / INSIGNA


INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer with Immunobiomarker SIGNature-driven Analysis

Physician and Research Staff Educational Material

This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material.

ECOG-ACRIN Cancer Research Group